NBC Securities Inc. Makes New Investment in AbCellera Biologics Inc. (NASDAQ:ABCL)

NBC Securities Inc. bought a new stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCLFree Report) in the third quarter, Holdings Channel reports. The fund bought 6,720 shares of the company’s stock, valued at approximately $30,000.

Several other large investors also recently bought and sold shares of ABCL. Worth Asset Management LLC acquired a new stake in AbCellera Biologics during the 1st quarter worth approximately $25,000. Point72 Asset Management L.P. purchased a new position in shares of AbCellera Biologics in the second quarter valued at $26,000. National Bank of Canada FI increased its holdings in shares of AbCellera Biologics by 392.7% in the 3rd quarter. National Bank of Canada FI now owns 6,085 shares of the company’s stock worth $27,000 after acquiring an additional 4,850 shares during the period. Point72 Middle East FZE acquired a new position in AbCellera Biologics during the 2nd quarter valued at about $30,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of AbCellera Biologics by 96.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,423 shares of the company’s stock worth $34,000 after purchasing an additional 3,638 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

AbCellera Biologics Stock Up 2.2 %

Shares of AbCellera Biologics stock opened at $5.02 on Friday. The business has a 50-day moving average price of $5.34 and a 200 day moving average price of $5.19. The firm has a market cap of $1.46 billion, a P/E ratio of -11.16 and a beta of 0.38. AbCellera Biologics Inc. has a fifty-two week low of $3.87 and a fifty-two week high of $10.59.

Analyst Ratings Changes

ABCL has been the subject of several recent research reports. Piper Sandler Companies reissued an “overweight” rating and set a $20.00 price objective on shares of AbCellera Biologics in a report on Friday, October 13th. KeyCorp initiated coverage on AbCellera Biologics in a research note on Tuesday, December 5th. They issued an “overweight” rating and a $6.00 price target on the stock. Benchmark cut AbCellera Biologics from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Bloom Burton reaffirmed a “buy” rating on shares of AbCellera Biologics in a research note on Friday, November 3rd. Finally, Piper Sandler restated an “overweight” rating and set a $20.00 price target on shares of AbCellera Biologics in a report on Friday, October 13th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, AbCellera Biologics presently has an average rating of “Moderate Buy” and an average target price of $20.38.

Read Our Latest Research Report on AbCellera Biologics

AbCellera Biologics Company Profile

(Free Report)

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.

Featured Articles

Want to see what other hedge funds are holding ABCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbCellera Biologics Inc. (NASDAQ:ABCLFree Report).

Institutional Ownership by Quarter for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.